A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Mantle Cell Lymphoma (MCL)
- Richter's Syndrome
- T-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Marginal Zone Lymphoma
- Myeloid Malignancies
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
- Myelodysplastic Syndrome (MDS)
- MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions
- DRUG: PRT2527
- DRUG: Zanubrutinib
- DRUG: Venetoclax
Sponsor
Prelude Therapeutics
Collaborators